Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913, An Investigational Genome Editing Treatment For MPS II, To Be Presented September 5th At SSIEM 2018 Symposium

RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis Type II (MPS II, also known as Hunter syndrome), will be presented at the 2018 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) being held in Athens, Greece from September 4-7^th.

The abstract, "Novel treatment of MPS II (Hunter Syndrome) with SB-913 ZFN-mediated in vivo human genome editing: Update from a Phase 1/2 clinical trial," is scheduled for an oral presentation on September 5^th during the Lysosomal Storage Disorders session beginning at 2:30pm local time (Eastern European Summer Time).

Webcasting services are not provided at this meeting.

About Sangamo Therapeutics 
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

Forward-Looking Statements
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the expected oral presentation of preliminary safety and efficacy data from the CHAMPIONS Study at the 2018 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM). Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the safety and efficacy of SB-913, the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of SB-913 and Sangamo's ability to develop commercially viable products for the treatment of MPS II and other diseases. For a more detailed discussion of these and other risks, please see Sangamo's SEC filings, including the risk factors described in its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo Therapeutics, Inc.